<PAGE>

                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

                    QUARTERLY REPORT FOR THE QUARTERLY PERIOD
                            ENDED SEPTEMBER 30, 2006

                           COMMISSION FILE NO. 0-28077

                                 GENELINK, INC.
                 (Name of Small Business Issuer in its charter)

<TABLE>
<S>                                     <C>                  <C>
          PENNSYLVANIA                    00-30518                23-2795613
(State or other jurisdiction of         (Commission            (I.R.S. Employer
 incorporation or organization)          File No.)           Identification No.)
</TABLE>

    Newport Financial Center, 13 Povonia Avenue, # 313, Jersey City, NJ 07310
                    (Address of principal executive offices)

                    ISSUER'S TELEPHONE NUMBER: (800) 558-4363

     Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes  X    No
                                              ---      ---

     Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes       No  X
                                                ---      ---

     APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares
outstanding of each of the issuer's classes of common stock, as of the latest
practicable date.

          Number of Shares of Common Stock
          Outstanding on November 1, 2006    39,491,430

     Transitional Small Business Disclosure Format   Yes       No  X
                                                         ---      ---

<PAGE>

                                 GENELINK, INC.

<TABLE>
<S>                                                                         <C>
PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements.

   Consolidated Balance Sheets at September 30, 2006 (unaudited) and
   December 31, 2005                                                           3

   Consolidated Statements of Operations for the three months and nine
   months ended September 30, 2006 and 2005 (unaudited)                      4-5

   Consolidated Statements of Cash Flows for the nine months ended
   September 30, 2006 and 2005 (unaudited)                                   6-7

   Notes to Financial Statements                                            8-10
</TABLE>


                                      -2-

<PAGE>

                          GENELINK, INC. AND SUBSIDIARY
                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                              (UNAUDITED)
                                                          SEPTEMBER 30, 2006   DECEMBER 31, 2005
                                                          ------------------   -----------------
<S>                                                       <C>                  <C>
ASSETS
Current Assets
   Cash                                                      $     19,065         $     15,275
   Accounts receivable                                             34,138               32,651
   Inventory                                                        6,504                3,261
   Prepaid expenses                                                17,861               37,435
                                                             ------------         ------------
      Total current assets                                         77,568               88,622
Property and equipment                                            144,700              147,519
Other assets                                                      325,333              209,135
                                                             ------------         ------------
      Total assets                                           $    547,601         $    445,276
                                                             ============         ============

LIABILITIES
Current liabilities
   Deferred revenue                                          $     22,148         $          0
   Accounts payable and accrued expenses                          419,556              429,165
   Accrued payroll taxes                                                0                7,454
   Loans payable                                                        0               27,861
                                                             ------------         ------------
      Total current liabilities                                   441,704              464,480

Loans payable                                                     515,890                    0
Accrued compensation                                              681,092              593,399
                                                             ------------         ------------
      Total liabilities                                         1,638,686            1,057,879
                                                             ------------         ------------

STOCKHOLDERS' EQUITY (DEFICIT)
Common stock, par value $0.01 per share; authorized:
   75,000,000 shares as of September 30, 2006 and
   December 31, 2005; issued: 39,923,988 and 36,689,550
   shares as of September 30, 2006 and December 31,
   2005, respectively; outstanding: 39,517,819 and
   36,283,381 shares as of September 30, 2006 and
   December 31, 2005, respectively                                399,240              366,896
Additional paid-in capital                                      6,977,899            6,910,160
Stock warrants                                                  2,991,209            2,961,809
Accumulated deficit                                           (11,144,378)         (10,536,413)
Treasury stock, 406,170 shares
   as of September 30, 2006 and
   December 31, 2005, at cost                                    (315,055)            (315,055)
                                                             ------------         ------------
Total shareholders' equity (deficiency)                        (1,091,085)            (612,603)
                                                             ------------         ------------
Total liabilities and shareholders' equity (deficiency)      $    547,601         $    445,276
                                                             ============         ============
</TABLE>

    The accompanying notes are an integral part of the consolidated financial
                                   statements


                                      -3-
<PAGE>

                          GENELINK, INC. AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
THREE MONTHS ENDED SEPTEMBER 30,                 2006          2005
--------------------------------             -----------   -----------
<S>                                          <C>           <C>
REVENUE                                      $    59,122   $    76,850
COST OF GOODS SOLD                                25,916        39,450
                                             -----------   -----------
GROSS PROFIT                                      33,206        37,400
                                             -----------   -----------
EXPENSES
   Selling, general and administrative           112,593       232,394
   Consulting                                     34,265        42,495
   Professional fees                              14,803        24,761
   Advertising and promotion                       1,450        13,294
   Amortization and depreciation                   8,793         7,030
                                             -----------   -----------
                                                 171,904       319,974
                                             -----------   -----------
NET LOSS BEFORE PROVISION FOR INCOME TAXES      (138,698)     (282,574)
PROVISIONS FOR INCOME TAXES                            0             0
                                             -----------   -----------
NET LOSS                                     $  (138,698)  $  (282,574)
                                             ===========   ===========
NET LOSS PER SHARE BASIC AND DILUTED         $    (0.003)  $    (0.008)
                                             ===========   ===========
Weighted average common shares and diluted
   potential common shares                    39,923,988    36,507,594
                                             ===========   ===========
</TABLE>

         The accompanying notes are an integral part of the consolidated
                              financial statements.


                                       -4-

<PAGE>

                          GENELINK, INC. AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,                  2006          2005
-------------------------------              -----------   -----------
<S>                                          <C>           <C>
REVENUE                                      $   142,458   $   361,548
COST OF GOODS SOLD                                53,643       149,240
                                             -----------   -----------
GROSS PROFIT                                      88,815       212,308
                                             -----------   -----------
EXPENSES
   Selling, general and administrative           362,970       817,412
   Consulting                                    138,989       142,946
   Professional fees                             155,895       131,945
   Advertising and promotion                       4,317       105,722
   Amortization and depreciation                  34,608        24,448
                                             -----------   -----------
                                                 696,779     1,222,473
                                             -----------   -----------
NET LOSS BEFORE PROVISION FOR INCOME TAXES      (607,964)   (1,010,165)
PROVISION FOR INCOME TAXES                             0             0
                                             -----------   -----------
NET LOSS                                     $  (607,964)  $(1,010,165)
                                             ===========   ===========
NET LOSS PER SHARE BASIC AND DILUTED         $     (0.02)  $     (0.03)
                                             ===========   ===========
Weighted average common shares and diluted
   potential common shares                    38,073,769    34,930,611
                                             ===========   ===========
</TABLE>

         The accompanying notes are an integral part of the consolidated
                              financial statements.


                                       -5-

<PAGE>

                          GENELINK, INC. AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,                               2006         2005
-------------------------------                            ---------   -----------
<S>                                                        <C>         <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss                                                   $(607,964)  $(1,010,165)
Adjustments to reconcile net loss to net cash
   used by operating activities
   Depreciation and amortization                              34,608        24,448
   Amortization of discounts on loans payable                 33,177        29,267
   Common stock issued for services                           24,326        46,034
   Fair value of options granted for consulting services           0        27,520
   Changes in operating assets and liabilities
      Accounts receivable                                     (1,487)      (15,787)
      Inventory                                               (3,243)       (3,316)
      Prepaid expenses                                        19,574         8,900
      Other assets                                            (4,272)       18,020
      Deferred revenue                                        22,148             0
      Accounts payable and accrued expenses                   (1,718)      168,160
      Accrued payroll taxes                                   (7,454)      (11,006)
      Accrued compensation                                    87,693       133,889
                                                           ---------   -----------
Net cash used in operating activities                       (404,612)     (584,036)
                                                           ---------   -----------
CASH FLOWS FROM INVESTING ACTIVITIES
   Capital expenditures                                      (18,322)      (58,311)
   Patent acquisition costs                                  (19,114)      (57,281)
                                                           ---------   -----------
Net cash used by investing activities                        (37,436)     (115,592)
                                                           ---------   -----------
CASH FLOWS FROM FINANCING ACTIVITIES
   Proceeds from loans and note payable                      358,541       212,600
   Repayment of loans and notes payable                      (17,861)      (25,000)
   Proceeds relating to issuance of common stock, net        103,158       419,900
                                                           ---------   -----------
Net cash provided by financing activities                    445,838       607,500
                                                           ---------   -----------
</TABLE>

         The accompanying notes are an integral part of the consolidated
                              financial statements.


                                       -6-
<PAGE>

                          GENELINK, INC. AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30,                                2006       2005
-------------------------------                              --------   --------
<S>                                                          <C>        <C>
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS         $  3,790   $(92,128)
Cash and cash equivalents, beginning of period                 15,275    155,689
                                                             --------   --------
Cash and cash equivalents, end of period                     $ 19,065   $ 63,561
                                                             --------   --------
SUPPLEMENTARY CASH FLOW INFORMATION
   Cash paid for interest                                    $  1,165   $      0

NON-CASH FINANCING TRANSACTIONS
   Issuance of common stock for services                     $ 24,326   $ 46,034
   Stock warrants granted for services                       $      0   $ 27,520
   Common stock and stock warrants granted for fundraising   $ 44,100   $      0
   Conversion of loans to common stock and warrants          $      0   $125,000
   Conversion of bridge loan and accrued interest to
      convertible secured loans                              $207,891   $      0
</TABLE>

    The accompanying notes are an integral part of the consolidated financial
                                   statements.


                                       -7-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                              NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1.   ORGANIZATION

GeneLink, Inc. (the Company) and Subsidiary (Dermagenetics, Inc.) operate in New
Jersey. The Company was organized under the laws of the Commonwealth of
Pennsylvania and Dermagenetics, Inc. was organized under the laws of the State
of Delaware. The Company is the successor to a Delaware corporation organized
under the same name on September 21, 1994. The Company's offices are located in
Jersey City, New Jersey.

The Company was founded in response to the information being generated in the
field of human molecular genetics. Scientists are discovering an increasing
number of connections between genes and specific diseases or physical attributes
and tendencies. These findings are a direct result of the National Institute of
Health Genome Project.

The Company has developed and received a patent on a DNA Collection Kit (R) for
the collection of DNA specimens of clients. The kit is classified as a
non-medical device.

The Company has also developed proprietary SNP-based genetic profiles (named
GeneLink Nutragenetic Profile (TM) and Dermagenetics (R) profiles. These
profiles provide a means of predicting an individual's inherent genetic capacity
to combat such conditions as oxidative stress and other important selected areas
of physiologic health. The profiles, for example, can measure a person's
potential to efficiently control oxygen free radical damage, eliminate hydrogen
peroxide, protect and repair oxidized phospholipids and destroy harmful
environmental compounds. The Company's profile assessment enables nutritional
and skin care companies and health care professionals to recommend a specific
and targeted regime of antioxidant vitamins, nutrients or skin care formulations
that have been specifically designed to compensate for predicted deficiencies
and to help provide individuals the best of health and appearance.

2.   BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared
by the Company in accordance with the instructions to Form 10-Q and Article 10
of Regulation S-X relating to interim financial statements. Accordingly, they do
not include all of the information and footnotes required by generally accepted
accounting principles for complete financial statements and should be read in
conjunction with the consolidated financial statements and notes thereto
included in the Annual Report on Form 10-K of GeneLink, Inc. and Subsidiary for
the year ended December 31, 2005.

In the opinion of management, all adjustments (consisting of normal recurring
accruals) necessary to present fairly the information set forth in the
accompanying consolidated financial statements have been included. The results
reported in these consolidated financial statements for the nine-month period
ended September 30, 2006 should not be regarded as necessarily indicative of
results that may be expected for the year ended December 31, 2006.


                                      -8-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                              NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

3.   DEFERRED REVENUE

The Company entered into an agreement with Rejuvenation Plus Pty Ltd for the
exclusive rights to distribute the Company's products in Australia and New
Zealand. In accordance with the agreement, Rejuvenation Plus paid the Company
$50,000 as a non-refundable credit to Rejuvenation Plus against future product
purchases. As of September 30, 2006, $22,148 is still available to offset future
purchases.

4.   LOANS PAYABLE

In January 2006, the Company entered into a Bridge Loan Agreement pursuant to
which the Company borrowed $200,000 and pledged all of its intellectual assets
as collateral. The Bridge Loan Financing accrues interest at a rate of 12% per
year and matures on December 31, 2006. In connection with the Bridge Loan
Agreement, the Company issued 400,000 shares of common stock to the Bridge
Lenders. All of the principal amount of and accrued interest on the $200,000
Bridge Loans entered into by the Company of January 12, 2006 converted into the
loans under the Convertible Secured Loan Agreement described below, and the
Company's obligations with respect to the Bridge Loans terminated along with the
security interest in its intellectual property granted by the Company to secure
such obligations.

On June 8, 2006, pursuant to the terms of a Convertible Secured Loan Agreement
dated May 12, 2006, the Company issued $497,890 of convertible secured loan
promissory notes and pledged all of its intellectual assets as collateral. The
notes accrue interest at a rate of 12% per year and mature on May 12, 2011. In
connection with the notes, the Company issued 2,489,452 shares of common stock
to the holders of the notes. Total funds received were allocated $382,993 to the
notes and $114,897 to the stock. The values assigned to both the notes and the
stock were allocated based on their relative fair values. The relative fair
value of the stock was recorded as common stock and additional paid in capital,
and reduced the carrying value of the notes. The discount on the notes is being
amortized to interest expense over the term of the notes.

The Company issued as fees for raising the funds invested pursuant to the Loan
Agreement an aggregate of 245,000 shares of its restricted common stock,
warrants to acquire 980,000 shares of its common stock at an exercise price of
$.05 per share and $34,300 in cash.

5.   SHAREHOLDERS' EQUITY TRANSACTIONS

The Company issued 100,000 shares of restricted common stock as payment for
legal services rendered.


                                      -9-

<PAGE>

                                                   GENELINK, INC. AND SUBSIDIARY
                              NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

6.   SUBSEQUENT EVENT

In October 2006, the Company borrowed $200,000 through a loan secured by
anticipated proceeds from the sale of net operating losses through the New
Jersey Technology Business Tax Certified Transfer Program (the Tax Transfer
Program). Through the Tax Transfer Program, the Company will sell at least
$250,000 of net operating loss benefits. The Company is scheduled to receive at
least $215,000 of net proceeds from such sale. It is anticipated that the
Company should receive such proceeds on or around December 31, 2006. This loan
bears interest at 20% per year and matures at the earlier of January 2007 or the
receipt of the net proceeds from the Tax Transfer Program. In connection with
the loan, the Company prepaid three months of interest.


                                      -10-

<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
     OF OPERATIONS

Statements in this Report that relate to future results and events are based on
the Company's current expectations. Actual results in future periods may differ
materially from those currently expected or desired because of a number of risks
and uncertainties. For a discussion of factors affecting the Company's business
and prospects, see "Item 2 - Management's Discussion and Analysis of Financial
Condition and Results of Operations - Factors Affecting the Company's Business
and Prospects."

Operating results for the nine-month period ended September 30, 2006 are not
necessarily indicative of the results that may be expected for the full fiscal
year ending December 31, 2006.

LIQUIDITY AND CAPITAL RESOURCES

For the nine month period ended September 30, 2006, the Company's primary
liquidity requirements have been the payment of operating expenses. In the first
nine months of 2006, the Company raised $497,890 through the issuance of loans.
In January 2006, the Company entered into a Bridge Loan Agreement pursuant to
which the Company borrowed $200,000 and pledged all of its intellectual assets
as collateral. The Bridge Loan Financing accrued interest at a rate of 12% per
year and was scheduled to mature on December 31, 2006. In connection with the
Bridge Loan agreement, the Company issued 400,000 shares of common stock to the
Bridge Lenders. On June 8, 2006, pursuant to the terms of a Convertible Secured
Loan Agreement dated May 12, 2006, the Company issued $497,890 of convertible
secured loan promissory notes and pledged all of its intellectual assets as
collateral. The notes accrue interest at a rate of 12% per year and mature on
May 12, 2011. In connection with the notes, the Company issued 2,489,452 shares
of common stock to the holders of the notes. All of the principal amount of and
accrued interest on the $200,000 Bridge Loans entered into by the Company of
January 12, 2006 converted into the loans under the Convertible Secured Loan
Agreement, and the Company's obligations with respect to the Bridge Loans
terminated along with the security interest in its intellectual property granted
by the Company to secure such obligations.

In October 2006, the Company borrowed $200,000 through a loan secured by
anticipated proceeds from the sale of net operating losses through the New
Jersey Technology Business Tax Certified Transfer Program (the "Tax Transfer
Program"). The loans accrue interest at a rate of 20% per year. The Company
received $190,000 of proceeds and prepaid $10,000 of interest. Through the Tax
Transfer Program, the Company will sell at least $250,000 of net operating loss
benefits. The Company is scheduled to receive at least $215,000 of net proceeds
from such sale. It is anticipated that the Company should receive such proceeds
on or around December 31, 2006. This loan bears interest at 20% per year and
matures at the earlier of January 2007 or the receipt of the net proceeds from
the Tax Transfer Program. In connection with the loan, the Company prepaid three
months of interest, or $10,000.

Cash and cash equivalents at September 30, 2006 amounted to $19,065 as compared
to $15,275 at December 31, 2005, an increase of $3,790. During the first nine
months of 2006, the Company's operating activities utilized $404,612, as
compared to $584,036 for the first nine months of 2005, a decrease of $179,424.
Cash utilized during the nine month period ended September 30, 2006 primarily
was used to fund a portion of the Company's $607,964 of net losses for such
period.


                                      -11-

<PAGE>

Financing activities provided $445,838 for the nine month period ended September
30, 2006 as compared to $607,500 for the nine months ended September 30, 2005, a
decrease of $161,662. Financing activities in the nine months ended September
30, 2006 resulted primarily from the issuance of $487,890 of loans.

Subject to required funding, the Company intends to use the proceeds to fund
various marketing initiatives that include: creating a "direct-to-consumer
retail website" for its Dermagenetics line of products; to continue seeking
additional international distribution opportunities for its products; to fund
the production of an "infomercial" regarding its Dermagenetics line of products;
to purchase inventory; to fund working capital; and to pay outstanding payables
and trade debt. The Company will require approximately $1,000,000 for these
purposes. The Company intends to raise funds through loans and/or the private
placement of its securities. Unless the Company can increase its revenues and
increase its stock price, it is unlikely that the Company will be able to secure
such financing. If the Company is not able to secure such additional required
capital, it will continue to realize negative cash flow and losses and may not
be able to continue operations.

  COMPARISON OF THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2006 TO THE THREE
                    AND NINE MONTHS ENDED SEPTEMBER 30, 2005

FINANCIAL CONDITION

Assets of the Company increased from $445,276 at December 31, 2005 to $547,601
at September 30, 2006, an increase of $102,325. This increase was primarily due
to an increase in other assets from $209,135 at December 31, 2005 to $325,333 at
September 30, 2006, an increase of $116,198, relating to deferred debt issuance
costs in connection with the notes and stock issued in connection with the
$497,890 of loans undertaken by the Company in June 2006.

Liabilities increased from $1,057,879 at December 31, 2005 to $1,638,686 at
September 30, 2006, an increase of $580,807. This increase in liabilities
primarily resulted from an increase in loans payable from $27,861 at December
31, 2005 to $515,890 at September 30, 2006, in connection with the $497,840
principal amount of loans issued in June 2006, together with an increase in
accrued compensation from $593,399 at December 31, 2005 to $681,092 at September
30, 2006, an increase of $87,693, as the Company accrued the salary of its
acting chief executive officer and compensation to its secretary and treasurer
due to cash flow constraints.

CURRENT YEAR PERFORMANCE AND EARNINGS OUTLOOK

Revenues. The total revenues for the nine months ended September 30, 2006 were
$142,458 as compared to $361,548 for the nine months ended September 30, 2005, a
decrease of $219,090. Total revenues for the three months ended September 30,
2006 were $59,122 as compared to $76,850 for the three months ended September
30, 2005, a decrease of $17,728. Revenues decreased primarily because the
Company did not have sufficient funds to implement its sales and marketing
strategies.

Expenses. Total expenses for the nine months ended September 30, 2006 were
$696,779 as compared to $1,222,473 for the nine months ended September 30, 2005,
a decrease of $525,694, primarily resulting from a decrease in selling, general
and administrative costs from $817,412 for the nine months ended September 30,
2005 to $362,970 for the nine months ended September 30,


                                      -12-

<PAGE>

2006, a decrease of $454,442, and a decrease in advertising and promotion
expenses from $105,722 for the nine months ended September 30, 2005 to $4,317
for the nine months ended September 30, 2006, a decrease of $101,405, as the
Company was unable to fully fund its business plan and promotional and marketing
efforts.

Total expenses for the three months ended September 30, 2006 were $171,904, as
compared to $319,974 for the months ended September 30, 2005, a decrease of
$148,070. This decrease primarily relates to a decrease in selling, general and
administrative expenses from $232,394 for the three months ended September 30,
2005 to $112,593 for the three months ended September 30, 2006, a decrease of
$119,801, and a decrease in advertising and promotion expenses from $13,294 for
the three months ended September 30, 2005 to $1,450 for the three months ended
September 30, 2006, a decrease of $11,844, each resulting from the Company not
having sufficient funds to implement its business plan and promotional and
marketing plans.

Losses. The Company incurred a loss of $607,964 for the nine months ended
September 30, 2006 as compared to a loss of $1,010,165 for the nine months ended
September 30, 2005, a decrease of $402,201. The Company incurred a loss of
$138,698 for the three months ended September 30, 2006, as compared to a loss of
$282,574 for the three months ended September 30, 2005, a decrease of $143,876.

FACTORS AFFECTING THE COMPANY'S BUSINESS AND PROSPECTS

There are a number of factors that affect the Company's business and the results
of its operations. These factors include general economic and business
conditions; the level of acceptance of the Company's products and services; the
rate and commercial applicability of advancements and discoveries in the
genetics field; the Company's ability to enter into strategic alliances with
companies in the health care, nutritional and skin-care industries; and the
ability of the Company to raise the financing necessary to implement its
business and marketing plan, to pay salaries to its officers and employees and
to pay its accounts payable.


                                      -13-

<PAGE>

ITEM 3. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

The Company maintains disclosure controls and procedures that are designed to
ensure that information required to be disclosed in its Exchange Act reports is
recorded, processed, summarized and reported within the time periods specified
in the Securities and Exchange Commission's rules and forms, and that such
information is accumulated and communicated to management, including the Acting
Chief Executive Officer and Acting Chief Financial Officer, as appropriate, to
allow timely decisions regarding required disclosure. Management necessarily
applies its judgment in assessing the costs and benefits of such controls and
procedures, which, by their nature, can provide only reasonable assurance
regarding management's control objectives.

With the participation of management, the Company's Acting Chief Executive
Officer and Acting Chief Financial Officer evaluated the effectiveness of the
design and operation of the Company's disclosure controls and procedures at the
conclusion of the three months ended September 30, 2005. Based upon this
evaluation, the Acting Chief Executive Officer and Acting Chief Financial
Officer concluded that the Company's disclosure controls and procedures were
effective in ensuring that material information required to be disclosed is
included in the reports that it files with the Securities and Exchange
Commission.

CHANGES IN INTERNAL CONTROLS

There were no significant changes in the Company's internal controls or, to the
knowledge of management of the Company, in other factors that could
significantly affect internal controls subsequent to the date of the Company's
most recent evaluation of its disclosure controls and procedures utilized to
compile information included in this filing.


                                      -14-

<PAGE>

PART II. OTHER INFORMATION

ITEM 6. Exhibits and Reports on Form 8-K.

     (a)  Exhibit No.

          31.1 Certification of Chief Executive Officer and Chief Financial
          Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

          32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted
          pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     (b)  Reports on Form 8-K.

          No reports on Form 8-K were filed during the quarter for which this
          report is filed.

                                   * * * * * *

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                        GENELINK, INC.
                                        (Registrant)


Date: November 13, 2006                 By: /s/ Monte E. Taylor, Jr.
                                            ------------------------------------
                                            Monte E. Taylor, Jr., Acting Chief
                                            Executive Officer and Acting
                                            Financial Officer


                                      -15-